Faculty Opinions recommendation of Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717964859.793469148 ◽

2013 ◽

Author(s):

Yiqian Nancy You ◽

Brian Keith Bednarski

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Download Full-text

Faculty Opinions recommendation of Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717965145.793466450 ◽

2012 ◽

Author(s):

Werner Scheithauer

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase 3 ◽

Previously Treated

Download Full-text

Faculty Opinions recommendation of Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718106825.793486219 ◽

2013 ◽

Author(s):

Siri Rostoft

Keyword(s):

Colorectal Cancer ◽

Elderly Patients ◽

Metastatic Colorectal Cancer ◽

Download Full-text

Upfront FOLFOXIRI Plus Bevacizumab and Reintroduction after Progression versus mFOLFOX6 Plus Bevacizumab Followed by FOLFIRI Plus Bevacizumab in the Treatment of Patients with Metastatic Colorectal Cancer (TRIBE2): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial by GONO

SSRN Electronic Journal ◽

10.2139/ssrn.3478102 ◽

2019 ◽

Author(s):

Chiara Cremolini ◽

Carlotta Antoniotti ◽

Daniele Rossini ◽

Sara Lonardi ◽

Fotios Loupakis ◽

...

Keyword(s):

Colorectal Cancer ◽

Randomised Controlled Trial ◽

Metastatic Colorectal Cancer ◽

Controlled Trial ◽

Phase 3 ◽

Open Label Phase ◽

Randomised Controlled

Download Full-text

Impact of tumor epidermal growth factor receptor (EGFR) status on the outcomes of first-line FOLFOX-4 ± cetuximab in patients (pts) with RAS-wild-type (wt) metastatic colorectal cancer (mCRC) in the randomized phase 3 TAILOR trial

Annals of Oncology ◽

10.1093/annonc/mdw370.75 ◽

2016 ◽

Vol 27 ◽

pp. vi174 ◽

Author(s):

S. Qin ◽

J. Xu ◽

L. Wang ◽

Y. Cheng ◽

T. Liu ◽

...

Keyword(s):

Colorectal Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Metastatic Colorectal Cancer ◽

Growth Factor Receptor ◽

Wild Type ◽

Phase 3 ◽

Epidermal Growth

Download Full-text

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70330-4 ◽

2014 ◽

Vol 15 (10) ◽

pp. 1065-1075 ◽

Author(s):

Volker Heinemann ◽

Ludwig Fischer von Weikersthal ◽

Thomas Decker ◽

Alexander Kiani ◽

Ursula Vehling-Kaiser ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Line Treatment ◽

Phase 3 ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Impact of Size and Location of Metastases on Early Tumor Shrinkage and Depth of Response in Patients With Metastatic Colorectal Cancer: Subgroup Findings of the Randomized, Open-Label Phase 3 Trial FIRE-3/AIO KRK-0306

Clinical Colorectal Cancer ◽

10.1016/j.clcc.2020.06.005 ◽

2020 ◽

Vol 19 (4) ◽

pp. 291-300.e5

Author(s):

Matthias F. Froelich ◽

Elina L. Petersen ◽

Volker Heinemann ◽

Dominik Nörenberg ◽

Nina Hesse ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Tumor Shrinkage ◽

Phase 3 ◽

Depth Of Response ◽

Early Tumor Shrinkage ◽

Open Label Phase ◽

Download Full-text

Phase 3 Correct Trial of Regorafenib in Metastatic Colorectal Cancer (MCRC): Overall Survival Update

Annals of Oncology ◽

10.1016/s0923-7534(20)34319-2 ◽

2012 ◽

Vol 23 ◽

pp. ixe10 ◽

Author(s):

E.J.D. Van Cutsem ◽

A. Grothey ◽

A. Sobrero ◽

S. Siena ◽

A. Falcone ◽

...

Keyword(s):

Colorectal Cancer ◽

Overall Survival ◽

Metastatic Colorectal Cancer ◽

Correct Trial ◽

Download Full-text

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

10.1016/s0140-6736(14)62004-3 ◽

2015 ◽

Vol 385 (9980) ◽

pp. 1843-1852 ◽

Author(s):

Lieke H J Simkens ◽

Harm van Tinteren ◽

Anne May ◽

Albert J ten Tije ◽

Geert-Jan M Creemers ◽

...

Keyword(s):

Colorectal Cancer ◽

Randomised Controlled Trial ◽

Metastatic Colorectal Cancer ◽

Maintenance Treatment ◽

Controlled Trial ◽

Phase 3 ◽

Cancer Group ◽

Randomised Controlled

Download Full-text

Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306)

Annals of Oncology ◽

10.1016/j.annonc.2019.10.001 ◽

2020 ◽

Vol 31 (1) ◽

pp. 72-78 ◽

Author(s):

J.W. Holch ◽

S. Held ◽

S. Stintzing ◽

L. Fischer von Weikersthal ◽

T. Decker ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Cancer Patients ◽

Skin Toxicity ◽

Tumor Shrinkage ◽

Phase 3 ◽

Early Tumor Shrinkage ◽

Early Tumor ◽

Colorectal Cancer Patients

Download Full-text

1609 Final results from PAVES, a phase 3, randomized, double-blind, placebo-controlled trial of pegfilgrastim in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab for locally advanced or metastatic colorectal cancer (LA/mCRC) (NCT00911170)

European Journal of Cancer ◽

10.1016/s0959-8049(16)30697-9 ◽

2015 ◽

Vol 51 ◽

pp. S241

Author(s):

T. Pinter ◽

P.K. Morrow ◽

A. Cesas ◽

A. Croitoru ◽

J. Decaestecker ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Controlled Trial ◽

Locally Advanced ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text